![]() |
市场调查报告书
商品编码
1801154
2025 年至 2033 年血液培养检测市场规模、份额、趋势及预测(依检测方法、产品、技术、应用、最终用户及地区)Blood Culture Test Market Size, Share, Trends and Forecast by Testing Method, Product, Technology, Application, End User, and Region, 2025-2033 |
2024年,全球血液培养检测市场规模达54.6亿美元。展望未来, IMARC Group预测,到2033年,该市场规模将达到108.7亿美元,2025年至2033年的复合年增长率为7.13%。北美目前占据市场主导地位,2024年将占据超过39.6%的市场。人群中细菌和真菌感染数量的增加、医院内感染(HAI)发病率的上升以及诊断技术的不断发展,是影响市场成长的一些关键驱动因素。
全球血液培养检测市场主要受血液感染发病率上升的驱动,尤其是败血症,败血症仍然是全球发病率和死亡率的主要原因。随着全球人口老化以及糖尿病和癌症等慢性疾病的增加,感染风险也随之上升,从而推动了对精准诊断检测的需求。例如,预计到2045年,全球将有7.83亿人患有糖尿病。此外,自动化系统和快速培养方法等诊断技术的进步提高了检测的准确性和效率,进一步推动了市场成长。这些创新使得更快地检测病原体成为可能,这对于及时治疗和改善患者预后至关重要。
对精准医疗和早期感染检测的日益重视是美国血液培养检测市场的主要驱动力。例如,2024 年 6 月,加州大学戴维斯分校健康研究人员获得了 560 万美元的资助,用于加强支持精准医疗的「我们所有人」研究计画。透过让不同人群参与,该计划旨在发现基因变异,促进个人化医疗,并促进所有人,特别是历史上代表性不足的群体获得公平治疗。医疗保健产业越来越重视精准的诊断方法,以应对抗生素抗药性细菌日益严重的挑战和慢性病日益流行的问题。血液培养检查在识别导致感染的病原体、促进制定个人化治疗计划以改善患者康復结果和遏制抗药性菌株传播方面发挥关键作用。这种重视正在推动美国医疗机构对这些诊断测试的需求。
细菌和真菌感染发生率上升
细菌和真菌感染病例的不断增加以及老年人口的增长是推动血液培养检测市场成长的主要动力。欧洲疾病预防控制中心2023年1月的报告显示,截至2022年12月31日,全球已确诊4,110,465例登革热病例,报告死亡病例4,099例。因此,对早期发现严重登革热相关併发症的需求日益增长,这推动了对血液检测的需求,而血液检测对于及时诊断该疾病至关重要,从而推动了市场成长。及时发现严重登革热病例的病情进展,再加上获得适当的医疗救治,可以将死亡率降低到1%以下。此外,一些主要的市场参与者正在推出创新的诊断解决方案,以应对日益增长的诊断数量。
院内感染(HAI)的盛行率不断上升
院内感染 (HAI) 是指患者在医疗机构接受其他健康状况治疗时感染的疾病。住院患者数量的增加导致 HIA 病例不断上升,进而刺激了血液培养检测市场的发展。此外,根据世界卫生组织的数据,每年进行近 2.35 亿次大型外科手术。美国疾病管制与预防中心在 2020 年《医院相关感染进展报告》中透露,当年美国报告了近 18,416 例手术部位感染。其中,6,094 例感染与结肠手术有关,2,173 例感染发生在髋关节置换术期间。医院获得性感染的激增催生了对强有力的血液培养检测的需求。此外,血液培养检测对于诊断和监测传染病至关重要,因此随着 HAI 发病率的上升,对这些检测的需求也随之增加。
诊断技术的新兴进展
自动化血液培养系统日益普及,该系统利用先进的边缘感测器和软体演算法,比传统方法更快、更准确地检测血液样本中的微生物生长,这成为市场成长的另一个重要驱动因素。各主要市场参与者正大力投资研发活动,以推出强大的自动化血液检测技术。例如,2022年12月,InsilicoMedicine推出了其智慧机器人药物发现实验室的第六代产品Life Star。这个完全自动化、由人工智慧驱动的机器人实验室旨在进行标靶发现、开发精准医疗、进行化合物筛选并支援转化研究。同样,2023年6月,太阳製药工业公司(Sun Pharmaceutical Industries)宣布计划加大对其特种药物和仿製药领域的研发投入。该公司表示,其目前在美国市场的仿製药产品线包括97个简化新药申请(ANDA),另有13个新药申请正在等待美国食品药物管理局(FDA)的批准。此外,各相关监管机构也采取措施加强诊断技术,这为整个市场带来了积极的前景。例如,医疗保险和医疗补助服务中心 (CMS) 是北美的一个监管机构,负责透过《临床实验室改进修正案》(CLIA) 监督和管理美国所有人体实验室检测,该修正案涵盖约 26 万个实验室实体。此外,人工智慧 (AI) 和机器学习 (ML) 演算法与血液培养分析的整合,使得快速分析大量资料集并预测结果成为可能。这反过来又有助于医疗专业人员做出明智的决策。
The global blood culture test market size was valued at USD 5.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 10.87 Billion by 2033, exhibiting a CAGR of 7.13% from 2025-2033. North America currently dominates the market, holding a significant market share of over 39.6% in 2024. The increasing number of bacterial and fungal infections in people, the growing rates of hospital-acquired infections (HAIs), and the evolving developments in diagnostic technology are some of the key drivers influencing the growth of the market.
The global blood culture test market is primarily driven by the rising incidence of bloodstream infections, particularly sepsis, which remains a leading cause of morbidity and mortality worldwide. As the global population ages and chronic conditions such as diabetes and cancer increase, the risk of infections rises, driving demand for accurate diagnostic tests. For instance, it is estimated that 783 million people globally will be living with diabetes by 2045. Additionally, advancements in diagnostic technologies, such as automated systems and rapid culture methods, have improved test accuracy and efficiency, further propelling market growth. These innovations enable faster detection of pathogens, which is critical for timely treatment and improved patient outcomes.
The growing emphasis on precision medicine and early infection detection is a key driver for the blood culture test market in the United States. For instance, in June 2024, UC Davis Health researchers received a USD 5.6 million grant to enhance the All of Us Research Program, which supports precision medicine. By engaging diverse populations, the initiative aims to uncover genetic variations, advancing personalized healthcare and promoting equitable treatment for all, especially historically underrepresented communities. The healthcare sector is increasingly prioritizing precise diagnostic methods to tackle the escalating challenges of antibiotic-resistant bacteria and the growing prevalence of chronic illnesses. Blood culture examinations play a critical role in identifying pathogens responsible for infections, facilitating the development of tailored treatment plans that improve patient recovery outcomes and curb the spread of resistant strains. This emphasis is driving the demand for these diagnostic tests across healthcare facilities in the United States.
The Rising Incidences of Bacterial and Fungal Infections
The escalating number of bacterial and fungal infections and a growing geriatric population are primarily driving the growth of the blood culture test market. The European Centre for Disease Prevention and Control's report from January 2023 revealed that by December 31, 2022, there were 4,110,465 confirmed cases of dengue and 4,099 reported fatalities. Consequently, the increasing need for early detection of severe dengue-related complications is fueling the demand for blood tests, which are essential for the prompt diagnosis of the disease, thereby driving market growth. Timely identification of disease progression in severe dengue cases, coupled with access to appropriate medical treatment, can reduce fatality rates to under 1%. In addition, several major market players are launching innovative diagnostic solutions to address the increasing number of diagnoses.
The Increasing Prevalence of Hospital-Acquired Infections (HAIs)
HAIs are infections that patients contract while undergoing treatment for other health conditions in medical settings. The increasing numbers of patients in hospital stays are leading to escalating cases of HIAs, which in turn is bolstering the market for blood culture tests. Additionally, according to the WHO, nearly 235 million major surgical procedures are performed every year. In its 2020 Healthcare-Associated Infection Progress Report, the Centers for Disease Control and Prevention revealed that nearly 18,416 surgical site infections were reported in the United States that year. Among these, 6,094 infections were linked to colon surgeries, while 2,173 occurred during hip arthroplasty procedures. Such a surge in hospital-acquired infections is catalyzing the need for robust blood culture tests. Moreover, blood culture tests are essential in diagnosing and monitoring infectious diseases, thus escalating the demand for these tests with the growing number of HAI rates.
The Emerging Advancements in Diagnostic Technology
The increasing adoption of automated blood culture systems, which use advanced edge sensors and software algorithms to detect microbial growth in blood samples more rapidly and precisely than traditional methods, is acting as another significant growth-inducing factor for the market. Various key market players are extensively investing in research and development activities to introduce robust automated blood testing technologies. For instance, in December 2022, InsilicoMedicine introduced Life Star, the sixth generation of its Intelligent Robotics Drug Discovery Laboratory. This fully automated, AI-driven robotics lab is designed to conduct target discovery, develop precision medicine, perform compound screening, and support translational research. Similarly, in June 2023, Sun Pharmaceutical Industries revealed plans to boost its investment in research and development for both its specialty and generics sectors. The company stated that its current generics pipeline for the U.S. market includes 97 Abbreviated New Drug Applications (ANDAs), with 13 new drug applications pending approval from the U.S. FDA. In addition to this, various concerned regulatory authorities are also taking initiatives to enhance diagnostics, which is creating a positive outlook for the overall market. For example, the Centers for Medicare & Medicaid Services (CMS) is a regulatory authority in North America responsible for overseeing and regulating all human laboratory testing in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA), which covers approximately 260,000 laboratory entities. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) algorithms into blood culture analysis is enabling a quick analysis of vast datasets and predicting outcomes. This, in turn, assists healthcare professionals in making informed decisions.
Conventional testing stands as the largest component in 2024, holding around 65.4% of the market. Conventional tests are employed in hospitals, clinics, and healthcare facilities across the globe. They serve as a fundamental diagnostic tool to identify the presence of bacteria, fungi, or other microorganisms in the bloodstream of the patient. Moreover, as these tests are essential for physicians to identify the appropriate course of treatment, various key market players are launching technologically advanced blood tests. In January 2022, Eurofins' subsidiary empowerDX introduced the PFAS Exposure test in the United States, a direct-to-consumer, at-home testing kit designed to measure the levels of per- and polyfluorinated alkyl substances (PFAS) in an individual's blood, including 47 different PFAS chemical compounds. Besides this, conventional tests are reliable, providing healthcare professionals with a well-established and trusted method for detecting bloodstream infections. This level of reliability is augmenting the demand for conventional tests.
Consumables lead the market with around 60.4% of market share in 2024. Consumables are employed at various essential junctures in the blood culture process. The American Cancer Society's 2022 statistics reported approximately 1,918,030 new cancer cases in the United States that year. The rising prevalence of diseases like cancer highlights the growing need for precision medicine, which in turn drives the demand for cell culture products and consumables essential for their development, fueling market growth. Moreover, various leading market players are increasingly focusing on research and development activities to develop improved cell culture products. In February 2022, KromaTiD introduced a complete range of services for cell and blood culture growth, isolation, processing, and quality control. The introduction of these products and services by companies like KromaTiD contributes to the rising demand for cell culture products and consumables, which is expected to drive the growth of this market segment.
Culture-based technology leads the market with around 66.5% of market share in 2024. Culture-based technology allows for the detection and identification of microbial pathogens, such as bacteria and fungi, in the blood samples of patients, which is essential in diagnosing bloodstream infections (BSIs) that can be life-threatening. As a result, various key companies are extensively investing in research activities to enhance culture-based technology. For example, in June 2022, Evonik introduced the cQrex portfolio of cell culture ingredients aimed at enhancing efficiency and productivity in bioprocesses for producing monoclonal antibodies, vaccines, viral vectors, and therapeutic cells. Similarly, in February 2022, CellulaREvolution secured GBP 1.75 million in funding to expedite the launch of its continuous cell culture technology. Furthermore, culture-based technology offers a high level of sensitivity. It can distinguish between several strains of microorganisms, allowing healthcare providers to customize their treatment strategies accordingly.
Bacterial infection leads the market with around 70.2% of market share in 2024. Bacterial infections are a prevalent concern in the healthcare sector. These infections can manifest in various forms, from mild to severe, and often require timely and accurate diagnosis for effective treatment. As a result, various healthcare institutions and pharmaceutical companies are increasingly investing in robust blood culture testing solutions. For example, in June 2022, Basilea Pharmaceutica Ltd reported positive topline results from the Phase III ERADICATE study, which assessed the effectiveness of ceftobiprole in treating adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB). Similarly, in May 2022, Nabriva Therapeutics PLC reached an agreement to extend its exclusive partnership with Merck & Co. Inc. subsidiaries for the promotion and distribution of SIVEXTRO (tedizolid phosphate), an antibiotic in the oxazolidinone class used to treat acute bacterial skin and skin structure infections (ABSSSI), in the United States until December 31, 2026. Moreover, ongoing technological advancements have enhanced the sensitivity and specificity of these tests, increasing their reliability in accurately detecting bacterial infections.
Hospital laboratories lead the market with around 53.8% of market share in 2024. Hospital laboratories are equipped with advanced technology and several resources, enabling them to conduct tests with a high degree of accuracy and efficiency. These laboratories often deliver more reliable results compared to other laboratories, due to which hospital laboratories are the go-to choice for healthcare professionals. Various healthcare facilities are investing in the establishment and expansion of advanced hospital laboratories. For example, in September 2021, Roche Diagnostics' Indian division introduced the Cobas Pure Integrated Solutions Analyzer, an advanced system designed to meet the needs of various laboratories and hospitals across the country.
In 2024, North America accounted for the largest market share of over 39.6%. The North American market is driven by the growing healthcare infrastructure that includes numerous networks of hospitals, clinics, and laboratories. Furthermore, the presence of a well-established healthcare insurance system in the region, ensuring that a substantial portion of the population has access to medical services, including blood culture testing, is also contributing to the region's growth. Furthermore, the introduction of technologically advanced blood tests in the United States is expected to positively influence market growth. For instance, in January 2022, Eurofins' subsidiary empowerDX launched the PFAS Exposure test in the U.S., a direct-to-consumer, at-home test designed to measure the levels of Per- and Polyfluorinated Alkyl Substances (PFAS) in an individual's blood and assess 47 of the PFAS "forever" chemical compounds. Moreover, in August 2021, Smart Meter introduced a glucose monitor specifically designed for managing gestational diabetes. This device offers an easy and reliable method for testing, monitoring, and managing blood glucose levels, ensuring that healthcare providers have immediate access to test results. Additionally, regulatory agencies in North America enforce stringent standards for healthcare products and services, fostering trust in these tests and making them the preferred option for both healthcare professionals and patients.
United States Blood Culture Test Market Analysis
The United States accounted for 80.4% of the market share in North America in 2024. The United States leads the North American blood culture test market, bolstered by a robust healthcare infrastructure, widespread adoption of advanced diagnostics, and a growing geriatric population highly susceptible to infections. According to data from the Centers for Disease Control and Prevention (CDC), there are more than 1.7 million healthcare-associated infections in the U.S. each year, fueling the demand for rapid and accurate blood culture testing solutions. Furthermore, the World Health Organization reports approximately 250,000 cases of bloodstream infections (BSIs) annually in the country, highlighting the significant burden of such conditions.
Furthermore, data from the U.S. Census Bureau shows that the population aged 65 and older increased by 38.6% between 2010 and 2020, reaching 55.8 million, which represents the fastest growth rate since the late 19th century. This demographic shift has amplified the demand for effective diagnostic tools to address age-related vulnerability to infections. These factors, combined with the presence of leading market players and increasing investments in R&D, have cemented the U.S. as a dominant force in the global blood culture test market.
Europe Blood Culture Test Market Analysis
Europe plays a key role in the global blood culture test market, fueled by growing healthcare investments, heightened awareness of sepsis management, and a strong emphasis on addressing antimicrobial resistance. The European Centre for Disease Prevention and Control (ECDC) estimates that around 4.3 million patients in hospitals across the EU/EEA acquire at least one healthcare-associated infection (HAI) each year during their hospital stay. These infections significantly contribute to the burden on healthcare systems and emphasize the need for effective diagnostic and infection control measures. Blood culture tests play a critical role in the early detection and management of bloodstream infections (BSIs) resulting from HAIs, enabling timely and targeted therapeutic interventions. This highlights the growing demand for advanced blood culture diagnostic solutions in Europe to address the challenges posed by healthcare-associated infections. By 2050, it is projected that the EU-27 will have close to half a Million centenarians, reflecting a significant shift in the region's demographic profile. In addition, the median age in the EU-27 is projected to increase by 4.5 years, reaching 48.2 years by 2050. This aging population underscores the increasing prevalence of age-related vulnerabilities, including bloodstream infections (BSIs) and sepsis, which are more common in older individuals. Additionally, the presence of leading diagnostic companies and increased R&D efforts, have positioned Europe as a key player in the global blood culture test market.
Asia Pacific Blood Culture Test Market Analysis
The Asia-Pacific region is witnessing a rapid demographic shift, with the United Nations Fund for Population Activities predicting the number of older individuals to triple by 2050, reaching 1.3 billion. Countries like Thailand, Japan, and China are witnessing a notable rise in aging populations, fueled by declining fertility rates and longer life expectancies. This demographic transformation is boosting demand for clinical laboratory services focused on geriatric care, disease management, and health monitoring, with a particular emphasis on diagnosing and managing infections in vulnerable populations. In Japan, this trend is further exacerbated by a surge in cases of streptococcal toxic shock syndrome (STSS), a dangerous bacterial infection with a mortality rate of up to 30%. As of June 2024, 977 cases of STSS had been recorded, surpassing last year's record-high infections, according to Japan's Health Ministry. The ongoing outbreak saw 77 fatalities between January and March, highlighting the need for enhanced diagnostic and infection management systems. The National Institute of Infectious Diseases reported 97 fatalities from STSS in 2023, making it the second-highest fatality rate in the past six years. These alarming statistics emphasize the critical role of advanced diagnostic tools, such as blood culture tests, in early detection and effective treatment of bloodstream infections and other life-threatening conditions.
Latin America Blood Culture Test Market Analysis
The blood culture test market in Latin America is expanding, driven by an increasing prevalence of infectious diseases, improving healthcare infrastructure, and rising awareness about early diagnostic tools. Countries like Brazil, Mexico, and Argentina are key contributors to the market, owing to their large populations and growing investments in healthcare systems. According to NIH statistics, in Brazilian intensive care units (ICUs), sepsis prevalence is 30% and hospital mortality rate for ICU patients is 55%. Studies from Colombia and Argentina also reported mortality rates for septic shock ranging from 45.6% to 51%. Governments and private healthcare providers are increasingly focusing on enhancing diagnostic capabilities, including the adoption of blood culture systems, to address this issue. As healthcare access improves across the region, the blood culture test market in Latin America is poised for steady growth, driven by increased investments in diagnostics and infection management.
Middle East and Africa Blood Culture Test Market Analysis
The Middle East and Africa (MEA) region represents an emerging market for blood culture tests, with growth driven by an increasing burden of infectious diseases, rising antimicrobial resistance, and improving healthcare access in developing economies. In resource-constrained areas within the region, bloodstream infections (BSIs) and sepsis often go undiagnosed or are diagnosed late, contributing to higher mortality rates. The World Health Organization (WHO) reports that infectious diseases continue to be a major cause of death in many African countries. Specifically, tuberculosis (TB) was the second leading cause of death from a single infectious agent, with nearly 2.5 million people affected and 424,000 lives lost in 2022. Governments and international health organizations are investing in improving laboratory capabilities, including the deployment of portable and cost-effective diagnostic systems. Furthermore, the rising prevalence of HAIs is prompting healthcare providers to adopt advanced diagnostic methods like blood culture systems to improve patient outcomes.
The global blood culture test market is highly competitive, with key players including diagnostic companies and medical device manufacturers offering advanced technologies for pathogen detection. Market leaders focus on delivering rapid, accurate results through automated systems, improved culture mediums, and enhanced identification methods. Competition is driven by innovations such as real-time PCR-based techniques and AI-powered diagnostic tools. Additionally, the rising demand for point-of-care testing and the need for faster diagnostics in critical care settings are fueling growth. Companies differentiate themselves by offering robust customer support, cost-effective solutions, and compliance with regulatory standards, ensuring their continued market presence in an increasingly crowded space. For instance, in August 2024, Orlando Health Orlando Regional Medical Center (ORMC), located in Central Florida, is the first hospital to use Abbott's innovative i-STAT TBI blood test, providing results in just 15 minutes. Developed with the Department of Defense, this rapid test helps assess patients with mild traumatic brain injuries, offering significant advancements in emergency care for quicker, more accurate diagnoses.